| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7391a11a4a22f8425562b11d62594b6d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_317710dee9e42d3e22f27ee22340d4ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dfb19c9e05b9eb07151318ebc5061748
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d6f67a4983cbb2664afbfb8a1452fe5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6424
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4743
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-805
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4723 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-805
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 |
| filingDate |
2006-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d8bc0f8b760720198773a60b0c294d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a81f24d74ceeadbd84df4d36cbba7cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7640135f172baa4db3eececde6c36241 |
| publicationDate |
2007-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2007045873-A2 |
| titleOfInvention |
Medical uses and therapies based upon the action of azurocidin on igfbp-1 |
| abstract |
The present invention concerns the use of azurocidin in the manufacture of a medicament for treating conditions associated with hepatic insulin resistance. Further provided is the use of a modulator of the interaction between azurocidin and IGFBP-1 in the manufacture of a medicament for use in the treatment of a condition which is associated with IGFBP-1 and/or IGF level and/or activity. Methods of treatment, an octopeptide modulator of amino acid sequence WDAISTYD, pharmaceutical compositions comprising the modulators of azurocidin and IGFBP-1 and uses thereof in the treatment of conditions associated with IGFBP-1 and/or IGF level and/or activity are also provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10126312-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9759720-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014080925-A1 |
| priorityDate |
2005-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |